Ajanta Pharma Q4 Profit Rises 11% to ₹2.25 Billion; Revenue Climbs on Strong Operational Performance

Ajanta Pharma Ltd has reported a robust set of numbers for the fourth quarter ended March 2025, with consolidated profit after tax rising 11% year-on-year to ₹2.25 billion. The company’s consolidated revenue from operations for the quarter stood at ₹11.7 billion, also registering an 11% growth compared to the same period last year.

 

The company’s EBITDA for Q4 reached ₹297 crore, up 6.8% year-on-year, reflecting improved operational efficiency despite a challenging cost environment. Ajanta Pharma’s performance was driven by healthy growth across its key therapeutic segments and continued momentum in both domestic and international markets.

 

For the full fiscal year, Ajanta Pharma reported a 10% increase in revenue to ₹4,648 crore and a 13% rise in profit after tax to ₹920 crore, underscoring its consistent growth trajectory. The company also maintained a strong return on capital employed (ROCE) at 32% and return on net worth (RONW) at 25%, highlighting its efficient capital management.

 

Ajanta Pharma’s management expressed confidence in sustaining growth, citing strategic investments in product innovation and market expansion. The company’s healthy free cash flow and disciplined financial approach position it well for future opportunities and value creation.

 

Source: MarketScreener, India Infoline, CNBC-TV18, Financial Express